Clinical trials: Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Study design This is a Phase II, open-label, multi-drug, multi-center, multi-arm, signal-searching study in patients with extensive-stage small-cell lung cancer (SCLC) who have refractory or resistant disease from prior…
- Trial name
- NCT02937818
- Testing
- Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib
- Where
- 12 sites in Germany, Hungary and 3 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca